Statement of Changes in Beneficial Ownership (4)
July 13 2020 - 2:40PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
|
1. Name and Address of Reporting Person
*
MERZOUKI ABDERRAZZAK |
2. Issuer Name and Ticker or Trading Symbol
Sunshine Biopharma, Inc
[
SBFM
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief Operating Officer |
|
(Last)
(First)
(Middle)
731 PLACE DE L'EEAU VIVE |
3. Date of Earliest Transaction
(MM/DD/YYYY)
10/20/2019 |
|
(Street)
LAVAL, A8 H7Y 2E1
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
| Common Stock | 10/20/2019 | | A | | 1100000 (1) | A | $0.001 | 2042500 (1) | D | |
| Common Stock | 12/19/2019 | | A | | 1300000 (1) | A | $0.001 | 3342500 (1) | D | |
| Common Stock | | | | | | | | 3668 (1)(2) | I | Held by Axis Biosciences, Inc. of which Reporting Person is a control person. |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code
(Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) | 8. Price of Derivative Security
(Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
| Explanation of Responses: |
| (1) | The amount of Securities Acquired and Securities Beneficially Owned reported herein are post the effectiveness of a February 1, 2019 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person and post the effectiveness of an April 6, 2020 reverse split of the Issuer's Common Stock wherein 1 share of Common Stock was issued for each 20 shares of Common Stock held by the Reporting Person. |
| (2) | The Indirect Shares Beneficially Owned are reported post effective of the reverse stock splits pursuant to Footnote 1. The Indirect holdings were previously reported as 2,193 post-reverse splits shares being held by 91138107 Quebec, Inc. and 1,475 post-reverse stock splits shares being held by Axis Biosciences, Inc. whereas 91138107 Quebec, Inc. and Axis Biosciences, Inc. are one and the same entity and are reported herein as being held by Axis Biosciences, Inc. of which Reporting Person is a control person. |
Reporting Owners
|
| Reporting Owner Name / Address | Relationships |
| Director | 10% Owner | Officer | Other |
MERZOUKI ABDERRAZZAK
731 PLACE DE L'EEAU VIVE
LAVAL, A8 H7Y 2E1 | X |
| Chief Operating Officer |
|
Signatures
|
| Abderrazzak Merzouki | | 7/13/2020 |
| **Signature of Reporting Person | Date |